You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Twelve hospitals will use the company's assays to screen vulnerable patients for genes from multi-drug resistant organisms.
The test is the first capable of simultaneously identifying Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa directly from blood cultures containing Gram-negative rods in less than 90 minutes.
The US Food and Drug Administration has granted 510(K) clearance for AdvanDx's 90-minute Yeast Traffic Light PNA FISH protocol for detecting Candida yeast.
AdvanDx received 510(k) clearance for 90-minute versions of its Escherichia coli/Pseudomonas aeruginosa and EK/P. aeruginosa diagnostic tests.
The new version of the peptide nucleic acid fluorescence in situ hybridization test takes 90 minutes instead of 2.5 hours for conventional tests.
According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.
CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.
Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.
In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.